S&P 500   3,819.72 (-1.31%)
DOW   31,270.09 (-0.39%)
QQQ   309.02 (-2.95%)
AAPL   122.04 (-2.46%)
MSFT   227.39 (-2.77%)
FB   255.41 (-1.39%)
GOOGL   2,014.74 (-2.41%)
TSLA   656.90 (-4.30%)
AMZN   3,011.00 (-2.70%)
NVDA   513.25 (-4.29%)
BABA   236.27 (+0.79%)
CGC   33.26 (-5.65%)
GE   13.44 (+3.54%)
MU   89.25 (-2.02%)
NIO   41.53 (-4.07%)
AMD   80.85 (-3.90%)
T   28.72 (+1.77%)
F   12.17 (-3.03%)
ACB   10.46 (-5.17%)
DIS   192.26 (-0.87%)
BA   228.56 (+2.43%)
NFLX   519.52 (-5.17%)
PFE   34.39 (+2.63%)
S&P 500   3,819.72 (-1.31%)
DOW   31,270.09 (-0.39%)
QQQ   309.02 (-2.95%)
AAPL   122.04 (-2.46%)
MSFT   227.39 (-2.77%)
FB   255.41 (-1.39%)
GOOGL   2,014.74 (-2.41%)
TSLA   656.90 (-4.30%)
AMZN   3,011.00 (-2.70%)
NVDA   513.25 (-4.29%)
BABA   236.27 (+0.79%)
CGC   33.26 (-5.65%)
GE   13.44 (+3.54%)
MU   89.25 (-2.02%)
NIO   41.53 (-4.07%)
AMD   80.85 (-3.90%)
T   28.72 (+1.77%)
F   12.17 (-3.03%)
ACB   10.46 (-5.17%)
DIS   192.26 (-0.87%)
BA   228.56 (+2.43%)
NFLX   519.52 (-5.17%)
PFE   34.39 (+2.63%)
S&P 500   3,819.72 (-1.31%)
DOW   31,270.09 (-0.39%)
QQQ   309.02 (-2.95%)
AAPL   122.04 (-2.46%)
MSFT   227.39 (-2.77%)
FB   255.41 (-1.39%)
GOOGL   2,014.74 (-2.41%)
TSLA   656.90 (-4.30%)
AMZN   3,011.00 (-2.70%)
NVDA   513.25 (-4.29%)
BABA   236.27 (+0.79%)
CGC   33.26 (-5.65%)
GE   13.44 (+3.54%)
MU   89.25 (-2.02%)
NIO   41.53 (-4.07%)
AMD   80.85 (-3.90%)
T   28.72 (+1.77%)
F   12.17 (-3.03%)
ACB   10.46 (-5.17%)
DIS   192.26 (-0.87%)
BA   228.56 (+2.43%)
NFLX   519.52 (-5.17%)
PFE   34.39 (+2.63%)
S&P 500   3,819.72 (-1.31%)
DOW   31,270.09 (-0.39%)
QQQ   309.02 (-2.95%)
AAPL   122.04 (-2.46%)
MSFT   227.39 (-2.77%)
FB   255.41 (-1.39%)
GOOGL   2,014.74 (-2.41%)
TSLA   656.90 (-4.30%)
AMZN   3,011.00 (-2.70%)
NVDA   513.25 (-4.29%)
BABA   236.27 (+0.79%)
CGC   33.26 (-5.65%)
GE   13.44 (+3.54%)
MU   89.25 (-2.02%)
NIO   41.53 (-4.07%)
AMD   80.85 (-3.90%)
T   28.72 (+1.77%)
F   12.17 (-3.03%)
ACB   10.46 (-5.17%)
DIS   192.26 (-0.87%)
BA   228.56 (+2.43%)
NFLX   519.52 (-5.17%)
PFE   34.39 (+2.63%)
Log in
NASDAQ:HGEN

Humanigen Competitors

$16.48
-1.21 (-6.84 %)
(As of 03/3/2021 03:59 PM ET)
Add
Compare
Today's Range
$16.10
Now: $16.48▼
$17.81
50-Day Range
$17.84
MA: $19.63▼
$23.83
52-Week Range
$1.75
Now: $16.48▼
$33.95
Volume37,873 shs
Average Volume821,665 shs
Market Capitalization$850.65 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.79

Competitors

Humanigen (NASDAQ:HGEN) Vs. LEGN, FGEN, APLS, AGIO, KRTX, and MOR

Should you be buying HGEN stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Humanigen, including Legend Biotech (LEGN), FibroGen (FGEN), Apellis Pharmaceuticals (APLS), Agios Pharmaceuticals (AGIO), Karuna Therapeutics (KRTX), and MorphoSys (MOR).

Humanigen vs. Legend Biotech Stock

Humanigen (NASDAQ:HGEN) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings.

Earnings & Valuation

This table compares Humanigen and Legend Biotech's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HumanigenN/AN/A$-10,290,000.00N/AN/A
Legend Biotech$64.39 million52.77$-132,970,000.00N/AN/A

Humanigen has higher earnings, but lower revenue than Legend Biotech.

Analyst Recommendations

This is a summary of current ratings and target prices for Humanigen and Legend Biotech, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Humanigen01502.83
Legend Biotech00303.00

Humanigen presently has a consensus target price of $27.8333, suggesting a potential upside of 68.89%. Legend Biotech has a consensus target price of $50.6667, suggesting a potential upside of 96.84%. Given Legend Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Legend Biotech is more favorable than Humanigen.

Insider & Institutional Ownership

30.2% of Humanigen shares are owned by institutional investors. Comparatively, 18.9% of Legend Biotech shares are owned by institutional investors. 37.5% of Humanigen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Humanigen and Legend Biotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
HumanigenN/A-302.90%-174.74%
Legend Biotech-543.73%-205.60%-43.03%

Humanigen vs. FibroGen Stock

Humanigen (NASDAQ:HGEN) and FibroGen (NASDAQ:FGEN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

Valuation & Earnings

This table compares Humanigen and FibroGen's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HumanigenN/AN/A$-10,290,000.00N/AN/A
FibroGen$256.58 million12.18$-76,970,000.00($0.89)-38.60

Humanigen has higher earnings, but lower revenue than FibroGen.

Analyst Ratings

This is a summary of current ratings and price targets for Humanigen and FibroGen, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Humanigen01502.83
FibroGen13402.38

Humanigen presently has a consensus target price of $27.8333, suggesting a potential upside of 68.89%. FibroGen has a consensus target price of $53.5714, suggesting a potential upside of 55.96%. Given Humanigen's stronger consensus rating and higher probable upside, research analysts clearly believe Humanigen is more favorable than FibroGen.

Risk and Volatility

Humanigen has a beta of -0.79, indicating that its share price is 179% less volatile than the S&P 500. Comparatively, FibroGen has a beta of 1.59, indicating that its share price is 59% more volatile than the S&P 500.

Insider and Institutional Ownership

30.2% of Humanigen shares are owned by institutional investors. Comparatively, 75.1% of FibroGen shares are owned by institutional investors. 37.5% of Humanigen shares are owned by insiders. Comparatively, 3.4% of FibroGen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Humanigen and FibroGen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
HumanigenN/A-302.90%-174.74%
FibroGen-191.78%-48.19%-27.72%

Summary

Humanigen beats FibroGen on 6 of the 11 factors compared between the two stocks.

Humanigen vs. Apellis Pharmaceuticals Stock

Humanigen (NASDAQ:HGEN) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

Valuation & Earnings

This table compares Humanigen and Apellis Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HumanigenN/AN/A$-10,290,000.00N/AN/A
Apellis PharmaceuticalsN/AN/A$-304,710,000.00($4.64)-9.83

Analyst Ratings

This is a summary of current ratings and price targets for Humanigen and Apellis Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Humanigen01502.83
Apellis Pharmaceuticals041012.80

Humanigen presently has a consensus target price of $27.8333, suggesting a potential upside of 68.89%. Apellis Pharmaceuticals has a consensus target price of $117.7857, suggesting a potential upside of 158.25%. Given Apellis Pharmaceuticals' higher probable upside, analysts clearly believe Apellis Pharmaceuticals is more favorable than Humanigen.

Risk and Volatility

Humanigen has a beta of -0.79, indicating that its share price is 179% less volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500.

Insider and Institutional Ownership

30.2% of Humanigen shares are owned by institutional investors. Comparatively, 81.2% of Apellis Pharmaceuticals shares are owned by institutional investors. 37.5% of Humanigen shares are owned by insiders. Comparatively, 9.5% of Apellis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Humanigen and Apellis Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
HumanigenN/A-302.90%-174.74%
Apellis PharmaceuticalsN/A-336.93%-78.28%

Summary

Apellis Pharmaceuticals beats Humanigen on 6 of the 10 factors compared between the two stocks.

Humanigen vs. Agios Pharmaceuticals Stock

Humanigen (NASDAQ:HGEN) and Agios Pharmaceuticals (NASDAQ:AGIO) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

Valuation & Earnings

This table compares Humanigen and Agios Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HumanigenN/AN/A$-10,290,000.00N/AN/A
Agios Pharmaceuticals$117.91 million27.11$-411,470,000.00($6.86)-6.72

Humanigen has higher earnings, but lower revenue than Agios Pharmaceuticals.

Analyst Ratings

This is a summary of current ratings and price targets for Humanigen and Agios Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Humanigen01502.83
Agios Pharmaceuticals02902.82

Humanigen presently has a consensus target price of $27.8333, suggesting a potential upside of 68.89%. Agios Pharmaceuticals has a consensus target price of $64.6364, suggesting a potential upside of 40.24%. Given Humanigen's stronger consensus rating and higher probable upside, research analysts clearly believe Humanigen is more favorable than Agios Pharmaceuticals.

Risk and Volatility

Humanigen has a beta of -0.79, indicating that its share price is 179% less volatile than the S&P 500. Comparatively, Agios Pharmaceuticals has a beta of 1.8, indicating that its share price is 80% more volatile than the S&P 500.

Insider and Institutional Ownership

30.2% of Humanigen shares are owned by institutional investors. Comparatively, 92.9% of Agios Pharmaceuticals shares are owned by institutional investors. 37.5% of Humanigen shares are owned by insiders. Comparatively, 3.2% of Agios Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Humanigen and Agios Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
HumanigenN/A-302.90%-174.74%
Agios Pharmaceuticals-170.65%-57.63%-37.15%

Summary

Agios Pharmaceuticals beats Humanigen on 6 of the 11 factors compared between the two stocks.

Humanigen vs. Karuna Therapeutics Stock

Humanigen (NASDAQ:HGEN) and Karuna Therapeutics (NASDAQ:KRTX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

Valuation & Earnings

This table compares Humanigen and Karuna Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HumanigenN/AN/A$-10,290,000.00N/AN/A
Karuna TherapeuticsN/AN/A$-43,960,000.00($3.68)-33.11

Analyst Ratings

This is a summary of current ratings and price targets for Humanigen and Karuna Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Humanigen01502.83
Karuna Therapeutics001103.00

Humanigen presently has a consensus target price of $27.8333, suggesting a potential upside of 68.89%. Karuna Therapeutics has a consensus target price of $141.70, suggesting a potential upside of 16.28%. Given Humanigen's higher probable upside, research analysts clearly believe Humanigen is more favorable than Karuna Therapeutics.

Risk and Volatility

Humanigen has a beta of -0.79, indicating that its share price is 179% less volatile than the S&P 500. Comparatively, Karuna Therapeutics has a beta of 2.07, indicating that its share price is 107% more volatile than the S&P 500.

Insider and Institutional Ownership

30.2% of Humanigen shares are owned by institutional investors. Comparatively, 74.8% of Karuna Therapeutics shares are owned by institutional investors. 37.5% of Humanigen shares are owned by insiders. Comparatively, 18.1% of Karuna Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Humanigen and Karuna Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
HumanigenN/A-302.90%-174.74%
Karuna TherapeuticsN/A-13.91%-13.72%

Summary

Karuna Therapeutics beats Humanigen on 6 of the 9 factors compared between the two stocks.

Humanigen vs. MorphoSys Stock

Humanigen (NASDAQ:HGEN) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

Analyst Ratings

This is a summary of current ratings and price targets for Humanigen and MorphoSys, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Humanigen01502.83
MorphoSys05302.38

Humanigen presently has a consensus target price of $27.8333, suggesting a potential upside of 68.89%. Given Humanigen's stronger consensus rating and higher probable upside, research analysts clearly believe Humanigen is more favorable than MorphoSys.

Risk and Volatility

Humanigen has a beta of -0.79, indicating that its share price is 179% less volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500.

Profitability

This table compares Humanigen and MorphoSys' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
HumanigenN/A-302.90%-174.74%
MorphoSys8.76%4.51%2.25%

Valuation & Earnings

This table compares Humanigen and MorphoSys' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HumanigenN/AN/A$-10,290,000.00N/AN/A
MorphoSys$80.43 million40.60$-115,380,000.00($0.91)-27.27

Humanigen has higher earnings, but lower revenue than MorphoSys.

Insider and Institutional Ownership

30.2% of Humanigen shares are owned by institutional investors. Comparatively, 3.1% of MorphoSys shares are owned by institutional investors. 37.5% of Humanigen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Humanigen beats MorphoSys on 6 of the 11 factors compared between the two stocks.


Humanigen Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
LEGN
Legend Biotech
1.2$25.74-2.1%$3.47 billion$64.39 million0.00Increase in Short Interest
Gap Down
FibroGen logo
FGEN
FibroGen
1.6$34.35-10.8%$3.46 billion$256.58 million-13.16Earnings Announcement
Analyst Downgrade
Unusual Options Activity
Analyst Revision
News Coverage
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$45.61-0.0%$3.45 billionN/A-6.15Earnings Announcement
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.6$46.09-6.1%$3.39 billion$117.91 million-9.35Earnings Announcement
Analyst Downgrade
Analyst Revision
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.6$121.86-2.2%$3.36 billionN/A-60.63Earnings Announcement
Analyst Report
Analyst Revision
MorphoSys logo
MOR
MorphoSys
0.4$24.82-2.5%$3.35 billion$80.43 million118.20News Coverage
Gap Up
Pacira BioSciences logo
PCRX
Pacira BioSciences
1.9$69.44-2.8%$3.10 billion$421.03 million24.45Earnings Announcement
Analyst Report
News Coverage
OPKO Health logo
OPK
OPKO Health
1.9$4.33-6.7%$3.10 billion$901.90 million-24.05
ALX Oncology logo
ALXO
ALX Oncology
1.9$83.88-0.6%$3.09 billionN/A0.00Upcoming Earnings
Decrease in Short Interest
News Coverage
Alkermes logo
ALKS
Alkermes
1.2$18.68-2.7%$3.06 billion$1.17 billion-40.61Analyst Revision
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.6$52.91-3.8%$3.03 billionN/A-29.07Earnings Announcement
Analyst Report
Analyst Revision
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$10.66-4.8%$2.91 billion$182.24 million-9.27Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.6$24.44-1.4%$2.91 billion$306.49 million27.46
Viela Bio logo
VIE
Viela Bio
0.8$52.95-0.0%$2.91 billion$50 million-7.54Earnings Announcement
Decrease in Short Interest
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$33.00-4.4%$2.79 billion$60,000.00-10.25Earnings Announcement
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$71.50-0.7%$2.75 billion$644.77 million-10.20Increase in Short Interest
IGMS
IGM Biosciences
1.8$81.23-9.9%$2.74 billionN/A-34.57
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.6$42.35-4.0%$2.74 billion$2.11 million-9.17Analyst Revision
PRLD
Prelude Therapeutics
1.0$59.89-4.4%$2.73 billionN/A0.00Upcoming Earnings
Xencor logo
XNCR
Xencor
1.0$44.80-2.8%$2.67 billion$156.70 million-32.00Analyst Upgrade
Analyst Revision
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.6$70.18-0.6%$2.61 billionN/A-26.09Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$34.55-5.0%$2.57 billion$15 million-18.09Analyst Report
Analyst Revision
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$44.31-0.0%$2.55 billion$25 million-8.86
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$147.69-3.5%$2.54 billion$120.28 million-149.18Decrease in Short Interest
Amarin logo
AMRN
Amarin
1.6$5.83-3.4%$2.34 billion$429.76 million-116.58Earnings Announcement
Cryoport logo
CYRX
Cryoport
1.7$55.12-7.1%$2.34 billion$33.94 million-95.03Earnings Announcement
Analyst Upgrade
News Coverage
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.8$29.01-1.7%$2.21 billion$23.90 million-18.02Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
MORF
Morphic
1.1$71.08-0.0%$2.21 billion$16.98 million-45.56Earnings Announcement
Analyst Report
Insider Selling
Decrease in Short Interest
News Coverage
Gap Down
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$22.83-6.2%$2.20 billionN/A-8.12
Generation Bio logo
GBIO
Generation Bio
1.4$40.00-4.3%$2.13 billionN/A0.00Upcoming Earnings
Analyst Report
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$42.31-0.7%$2.09 billion$963.01 million13.14
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
1.3$58.74-1.8%$2.09 billionN/A0.00Upcoming Earnings
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.0$59.13-1.5%$2.01 billionN/A-32.85
HRMY
Harmony Biosciences
1.2$34.77-0.4%$1.99 billionN/A0.00Upcoming Earnings
Analyst Downgrade
Kura Oncology logo
KURA
Kura Oncology
1.6$29.93-0.2%$1.99 billionN/A-18.36Earnings Announcement
Analyst Report
Analyst Revision
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.7$28.50-4.4%$1.88 billion$103.54 million-21.43Insider Selling
ADCT
ADC Therapeutics
1.6$25.42-6.5%$1.87 billion$2.34 million-10.77Upcoming Earnings
News Coverage
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
2.0$14.37-0.3%$1.84 billion$320,000.00-9.78Analyst Revision
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.1$61.65-0.7%$1.81 billion$970,000.000.00Upcoming Earnings
Increase in Short Interest
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$17.66-11.1%$1.79 billion$34.51 million-15.09Earnings Announcement
Analyst Report
News Coverage
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$112.54-1.6%$1.77 billionN/A-10.17Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.6$43.58-0.2%$1.77 billionN/A0.00Upcoming Earnings
ImmunoGen logo
IMGN
ImmunoGen
1.3$8.70-4.3%$1.77 billion$82.27 million-21.22
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$32.67-7.3%$1.75 billionN/A-3.54
Shattuck Labs logo
STTK
Shattuck Labs
1.3$41.28-1.1%$1.74 billionN/A0.00Upcoming Earnings
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$25.82-0.9%$1.73 billion$410,000.00-5.61Analyst Report
ORGO
Organogenesis
1.0$15.44-3.6%$1.73 billion$260.98 million-257.33
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$45.59-4.9%$1.72 billionN/A0.00Upcoming Earnings
News Coverage
Zymeworks logo
ZYME
Zymeworks
1.8$34.16-7.2%$1.69 billion$29.54 million-9.06Earnings Announcement
Analyst Report
Increase in Short Interest
Analyst Revision
News Coverage
Endo International logo
ENDP
Endo International
1.1$6.85-5.5%$1.67 billion$2.91 billion-10.07Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
This page was last updated on 3/3/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.